Serious adverse events: cardiovascular events · dialysis vascular access outcomes in AVG patients with ESKD
It is very uncertain whether omega‐3 fatty acids changes serious adverse events: cardiovascular events compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events: major bleeding · dialysis vascular access outcomes in AVG patients with ESKD
It is very uncertain whether omega‐3 fatty acids changes serious adverse events: major bleeding compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events: death · Dialysis vascular access outcomes in AVF patients with ESKD
Omega‐3 fatty acids showed no clear difference in serious adverse events: death compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events: hospitalisation · Dialysis vascular access outcomes in AVF patients with ESKD
Omega‐3 fatty acids showed no clear difference in serious adverse events: hospitalisation compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events: cardiovascular events · Dialysis vascular access outcomes in AVF patients with ESKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events: major bleeding · Dialysis vascular access outcomes in AVF patients with ESKD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Loss of patency by 12 months · dialysis vascular access outcomes in AVG patients with ESKD
It is very uncertain whether omega‐3 fatty acids changes loss of patency by 6 months compared with placebo (very low certainty).
2 findings from 1 review
Serious adverse events: death · dialysis vascular access outcomes in AVG patients with ESKD
Omega‐3 fatty acids showed no clear difference in serious adverse events: death compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events: hospitalisation · dialysis vascular access outcomes in AVG patients with ESKD
It is very uncertain whether omega‐3 fatty acids changes serious adverse events: hospitalisation compared with placebo (very low certainty).
1 finding from 1 review
Change in visual loss associated with PSR: visual loss is defined by the deterioration of visual acuity of 3 lines or more with the Snellen chart · people with AMD
Omega 3 fatty acids probably leads to higher loss of 3 or more lines of VA at 24 months compared with placebo (moderate certainty).
2 findings from 1 review
Incidence of CNV at 24 months · people with AMD
Omega 3 fatty acids probably leads to higher incidence of CNV at 24 months compared with placebo (moderate certainty).
1 finding from 1 review
Incidence of CNV at 36 months · people with AMD
Omega 3 fatty acids probably leads to higher incidence of CNV at 36 months compared with placebo (moderate certainty).
1 finding from 1 review
Progression of AMD (dichotomous) · people with AMD
Omega 3 fatty acids showed no clear difference in progression of AMD over 5 years compared with placebo (high certainty).
1 finding from 1 review
Adverse effects · people with AMD
Omega 3 fatty acids leads to higher adverse effects compared with placebo (high certainty).
1 finding from 1 review
Proportion of participants achieving clear or almost clear skin (PASI 90 to 100 or PGA 0 to 1) · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Percentage of participants with adverse effects and severe adverse effects · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of relapses of guttate psoriasis or flares within a period of 6 months after the treatment has finished · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants achieving PASI 75 or PGA 1 to 2 · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in participant satisfaction measures and quality of life assessment measures Overall subjective score on 5 items (appearance of lesions, impairment of daily life, pruritus, burning, and pain) reported through figures · guttate psoriasis
1 finding from 1 review
Language development ‐ Beyond 24 months · Breastfeeding mothers
1 finding from 1 review